EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population

Nieminen, Markku S.; Brutsaert, Dirk L.; Dickstein, Kenneth; Drexler, Helmut; Folláth, Ferenc; Harjola, Veli‐Pekka; Hochadel, Matthias; Komajda, Michel; Lassus, Johan; López‐Sendón, José; Ponikowski, Piotr; Tavazzi, Luigi

doi:10.1093/eurheartj/ehl193

Cited by 1,122 publications

(1,050 citation statements)

References 24 publications

Supporting

Mentioning

867

Contrasting

Unclassified

Order By: Relevance

“…Also of importance is the fact that identification of CAD patients was based not only on clinical grounds, but also on coronary angiography data available in 69% of them, but also in 43% of those with non‐CAD. This is in contrast to most existing series of APE7, 10, 23 or acute heart failure,1, 2, 3, 4, 5, 13 where angiographic data are not provided. Of interest is the documentation of significant coronary artery stenosis in 32% of non‐CAD patients who underwent cardiac catheterization, pointing to the concomitant presence of CAD in patients with the primary diagnosis of valvular heart disease.…”

Section: Discussionmentioning

confidence: 90%

“…Several investigators have reported on the in‐hospital mortality in patients with acute heart failure, which is an ample concept that includes acute decompensation of chronic heart failure, cardiogenic shock with or without pulmonary edema, right ventricular failure, and APE 3, 6, 14, 19, 20, 21. In these studies, mortality has varied from 6.4% to 17.2% and they have shown advanced age,6, 14, 19, 21 severe left ventricular dysfunction,14 acute coronary syndromes,14 admission blood pressure,6, 19, 21 renal failure,6, 19, 21 need for inotropics,19 and anemia19 as principal predictors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hospital and 4‐Year Mortality Predictors in Patients With Acute Pulmonary Edema With and Without Coronary Artery Disease

Figueras

Bañeras

Peña‐Gil

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundLong‐term prognosis of acute pulmonary edema (APE) remains ill defined.Methods and ResultsWe evaluated demographic, echocardiographic, and angiographic data of 806 consecutive patients with APE with (CAD) and without coronary artery disease (non‐CAD) admitted from 2000 to 2010. Differences between hospital and long‐term mortality and its predictors were also assessed. CAD patients (n=638) were older and had higher incidence of diabetes and peripheral vascular disease than non‐CAD (n=168), and lower ejection fraction. Hospital mortality was similar in both groups (26.5% vs 31.5%; P=0.169) but APE recurrence was higher in CAD patients (17.3% vs 6.5%; P<0.001). Age, admission systolic blood pressure, recurrence of APE, and need for inotropics or endotracheal intubation were the main independent predictors of hospital mortality. In contrast, overall mortality (70.0% vs 57.1%; P=0.002) and readmission for nonfatal heart failure after a 45‐month follow‐up (10–140; 17.3% vs 7.6%; P=0.009) were higher in CAD than in non‐CAD patients. Age, peripheral vascular disease, and peak creatine kinase MB during index hospitalization, but not ejection fraction, were the main independent predictors of overall mortality, whereas coronary revascularization or valvular surgery were protective. These interventions were mostly performed during hospitalization index (294 of 307; 96%) and not intervened patients showed a higher risk profile.ConclusionsLong‐term mortality in APE is high and higher in CAD than in non‐CAD patients. Considering the different in‐hospital and long‐term mortality predictors herein described, which do not necessarily involve systolic function, it is conceivable that a more aggressive interventional program might improve survival in high‐risk patients.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Hospital and 4‐Year Mortality Predictors in Patients With Acute Pulmonary Edema With and Without Coronary Artery Disease

Figueras

Bañeras

Peña‐Gil

et al. 2016

JAHA

View full text Add to dashboard Cite

show abstract

“…Acute decompensated HF (ADHF) is the most common cause of hospitalization,3 and cardiogenic shock occurs in about 4% of ADHF admissions 4. Conventional inotropes improve haemodynamics and organ perfusion and relieve symptoms, but due to short half‐lives, they are limited to selected inpatients and outpatients with continuous infusions and are pro‐ischaemic, are pro‐arrhythmic, and may be associated with increased mortality 5, 6, 7, 8, 9…”

Section: Introductionmentioning

confidence: 99%

Haemodynamic effects of levosimendan in advanced but stable chronic heart failure

et al. 2018

View full text Add to dashboard Cite

AimsLevosimendan improves haemodynamics in acute decompensated heart failure (HF). However, it is increasingly used for repetitive or intermittent infusions in advanced but stable chronic HF, without clear indication, selection criteria, or effect. We tested the hypotheses that (1) levosimendan improves haemodynamics in stable chronic HF and (2) that the response is dependent on baseline clinical and haemodynamic factors.Methods and resultsTwenty‐three patients [median age 56 (49–64) years, four (17%) women] with stable New York Heart Association (NYHA) III and IV HF received a single 24 h levosimendan infusion. Non‐invasive haemodynamics (inert gas re‐breathing technique), estimated glomerular filtration rate, and N‐terminal pro‐brain natriuretic peptide were assessed before and after infusion. Levosimendan had the following effects (median change): a significant increase in cardiac output (+9.8 ± 21.6%; P = 0.026) and decrease in N‐terminal pro‐brain natriuretic peptide (−28.1 ± 16.3%, P < 0.001), estimated total peripheral resistance (−16.9 ± 18.3%, P = 0.005), and mean arterial pressure (−5.9 ± 8.2%, P = 0.007), but no change in estimated glomerular filtration rate (+0.89 ± 14.0%, P = 0.955). There were no significant associations between baseline clinical and/or haemodynamic factors and the levosimendan effect on cardiac output.ConclusionsLevosimendan was associated with improved haemodynamics in patients with stable chronic HF, but we could not identify any predictors of the magnitude of haemodynamic response.

show abstract

“…Heart failure (HF) is a global public health problem affecting millions worldwide 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12. In the USA, the prevalence is 5.7 million and there are 670 000 new cases per year, while there are another 15 million people living with HF in Europe 13, 14, 15.…”

Section: Introductionmentioning

confidence: 99%

“…1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 These registries have either focused on in‐patient characterization and short‐term outcomes or maintained separate samples of acute HF hospitalizations and chronic HF follow‐up, limiting understanding of the transition from chronic maintenance to an acute state requiring hospitalization 24, 25. No prior detailed, longitudinal evaluations of long‐term disease progression, healthcare utilization, and health economics on a global scale have been reported.…”

Section: Introductionmentioning

confidence: 99%

International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT‐HF): rationale for and design of a global registry

Filippatos

Khan

Ambrosy

et al. 2015

European J of Heart Fail

View full text Add to dashboard Cite

AimsThe clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new‐onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT‐HF (International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure) is a global, prospective, and observational study designed to characterize patient trajectories longitudinally during and following an index hospitalization for HF.MethodsData collection for the registry will be conducted at ∼300 sites located in ∼40 countries. Comprehensive data including demographics, clinical presentation, co‐morbidities, treatment patterns, quality of life, in‐hospital and post‐discharge outcomes, and health utilization and costs will be collected. Enrolment of ∼20 000 adult patients hospitalized with new‐onset (first diagnosis) HF or decompensation of chronic HF over a 3‐year period is planned with subsequent 3 years follow‐up.PerspectiveThe REPORT‐HF registry will explore the clinical characteristics, management, and outcomes of HF worldwide. This global research programme may have implications for the formulation of public health policy and the design and conduct of international clinical trials.

show abstract

EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population

Cited by 1,122 publications

References 24 publications

Hospital and 4‐Year Mortality Predictors in Patients With Acute Pulmonary Edema With and Without Coronary Artery Disease

Hospital and 4‐Year Mortality Predictors in Patients With Acute Pulmonary Edema With and Without Coronary Artery Disease

Haemodynamic effects of levosimendan in advanced but stable chronic heart failure

International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT‐HF): rationale for and design of a global registry

Contact Info

Product

Resources

About